Results 201 to 210 of about 188,535 (344)

Ferroptosis: The Demise of Cells Through Phospholipid Peroxidation

open access: yesAdvanced Science, EarlyView.
The relative abundance of peroxidation‐resistant monounsaturated fatty acids (MUFAs) vs. peroxidation‐sensitive polyunsaturated fatty acids (PUFAs) incorporated into phospholipid (PL) is a key determinant of ferroptosis sensitivity, as the peroxidation of PL PUFA acyl chains (PUFA‐PL) disrupts membrane integrity, causing ferroptotic cell death ...
Shaojie Cui, Jin Ye
wiley   +1 more source

CARDIOMETABOLIC RISK PREDICTION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE COMBINED WITH SUBCLINICAL HYPOTHYROIDISM

open access: diamond, 2023
Olena Kolesnikova   +8 more
openalex   +2 more sources

Nanozymes for Liver Disease Therapy: Advances in Catalytic Activity, Targeting Strategies, and Clinical Translation

open access: yesAdvanced Science, EarlyView.
Nanozymes, as enzyme‐mimicking nanomaterials, exhibit unique catalytic properties for the treatment of liver diseases. By regulating redox homeostasis, modulating immune responses, and enabling targeted delivery, nanozymes overcome the limitations of natural enzymes.
Xiandi Meng   +6 more
wiley   +1 more source

Vascularized Cardiac Tissue Engineering: From Advances in Biofabrication to Translational Applications

open access: yesAdvanced Science, EarlyView.
This review presents a process‐oriented framework for vascularized cardiac tissue engineering, highlighting how the coordinated design of cells, biomaterials, and biofabrication strategies enables the functional development or vascularized myocardium for disease modelling and drug discovery.
Yang Liu   +9 more
wiley   +1 more source

Molecular characterization of the A52 murine hepatocellular carcinoma cell line

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Hepatocellular carcinoma (HCC) is a poor outcome cancer with limited therapeutic choices. To advance therapeutic development we genetically characterized the A52 murine HCC cell line. We noted genetic changes that match a subset of human HCC and this offers the opportunity to test novel targeted therapies in syngeneic mice.
Rhys Gillman   +5 more
wiley   +1 more source

Diagnosis and Management of Pediatric Non-Alcoholic Fatty Liver Disease: An Overview. [PDF]

open access: yesMetabolites
Dop D   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy